Clinical trials: Metastatic Colorectal Carcinoma
Melanoma, Renal Cell Carcinoma
A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
In this four-part study, NKTR-214 was administered in combination with nivolumab and with/without other anticancer therapies. Part 1 considered escalating doublet (NKTR 214 + nivolumab) doses to determine the RP2D.
- Conditions
- Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- PIVOT-02 (NCT02983045)
- Testing
- Dose Escalation Doublet: Combination of NKTR-214 + nivolumab, Dose Expansion Doublet: Combination of NKTR-214 + nivolumab, Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab
- Where
- 58 sites in United States, Belgium and 6 more
- Volunteers
- 557 people
- Sponsor
- Nektar Therapeutics
Colon Cancer
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
This non-randomized phase II study is designed to assess the response rate and toxicity of weekly topotecan as second-line treatment in patients with relapsed or refractory metastatic colorectal cancer.
- Trial name
- NCT00193167
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- SCRI Development Innovations, LLC
Metastatic Colorectal Cancer
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
The purpose of the study is to investigate the effect and side effects of personalized cancer treatment in patients with metastatic colorectal cancer (bowel cancer).
- Trial name
- EVIDENT (NCT05725200)
- Testing
- Alectinib, Cetuximab, Crizotinib
- Where
- Norway
- Volunteers
- 40 people
- Sponsor
- Oslo University Hospital
Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma
CBX-12 for the Treatment of Metastatic Chemotherapy-Refractory Microsatellite Stable Colorectal Cancer
This phase II trial studies how well CBX-12 works in treating patients with microsatellite stable colorectal cancer that has spread to other parts of the body (metastatic) and is no longer responding to chemotherapy treatment…
- Conditions
- Metastatic Mismatch Repair Proficient Colorectal Carcinoma, Refractory Mismatch Repair Proficient Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8
- Trial name
- NCT06730100
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 15 sites in United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer
Colonic Stent and Tumor Cell Dissemination
This study aims to examine the hypothesis of tumor cell dissemination after colonic stenting for obstructing colorectal cancer by measuring the level of plasma circulating tumor cell before and after the procedure of successful…
- Trial name
- NCT01628328
- Volunteers
- 40 people
- Sponsor
- The University of Hong Kong
Colorectal Cancer
Pembrolizumab for Locally Advanced, Irresectable, Non-metastatic dMMR Colorectal Cancers
In this study, the efficacy of pembrolizumab in patients with locally advanced, irresectable dMMR colorectal cancer will be assessed.
- Trial name
- PUMA (NCT05131919)
- Testing
- Pembrolizumab
- Where
- Netherlands
- Volunteers
- 25 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Colorectal Cancer
Sequential Treatment Strategy for Metastatic Colorectal Cancer
Study Design: This is a pragmatic study on the management strategy for patients with metastatic colorectal cancer (CRC) who are candidates for CT, independently of any previous adjuvant therapy received.
- Trial name
- ITACa (NCT01878422)
- Testing
- Arm A: FOLFIRI or FOLFOX + Bevacizumab, Arm B: FOLFIRI or FOLFOX, Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
- Where
- 23 sites in Italy
- Volunteers
- 376 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
This phase I trial studies the side effects and best dose of M6620 and irinotecan hydrochloride in treating patients with solid tumors that have spread to other places in the body (metastatic) or cannot be removed by surgery…
- Conditions
- Metastatic Colorectal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Carcinoma
- Trial name
- NCT02595931
- Testing
- Berzosertib, Biopsy Specimen, Biospecimen Collection
- Where
- 23 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Colorectal Cancer, Colorectal Cancer
Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)
The purpose of this study is to evaluate whether therapy with MORAb-004 is effective and safe in the treatment of metastatic, colorectal cancer.
- Trial name
- NCT01507545
- Testing
- MORAb-004, Best supportive care
- Where
- 67 sites in United States
- Volunteers
- 154 people
- Sponsor
- Morphotek
Colorectal (Colon or Rectal) Cancer
Collagenase Biobank Study
The purpose of this study is to look at how bacteria present within the stool at the time of surgery and postoperatively may contribute to the development of cancer recurrence after surgery.
- Trial name
- NCT07211230
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- University of Chicago
Colorectal Cancer
An Observational Study of First-Line Capecitabine Based Chemotherapy in Participants With Metastatic Colorectal Cancer
This observational study will evaluate the efficacy and safety of different capecitabine based chemotherapies, alone or in combination with other therapies, as first line treatment of metastatic colorectal cancer in participants…
- Trial name
- AXEL (NCT01696695)
- Testing
- Capecitabine, Chemotherapy
- Where
- 22 sites in Hungary
- Volunteers
- 882 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Non-small Cell Lung Cancer
A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors
This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other cancer treatments in participants with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT07623369
- Testing
- HH160
- Where
- 3 sites in Australia, China
- Volunteers
- 299 people
- Sponsor
- Huahui Health
Stage IV Colorectal Cancer
Exercise Program During Chemotherapy in Metastatic Colorectal Cancer
This pilot clinical trial studies how well aerobic exercise works in improving quality of life and health-related outcomes in patients with stage IV colorectal cancer undergoing chemotherapy.
- Trial name
- NCT03111823
- Testing
- Exercise Intervention, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 2 sites in United States
- Volunteers
- 2 people
- Sponsor
- University of Southern California
Hepatocellular Carcinoma, Cholangiocarcinoma
Liver Embolization Approaches for Tumor Management
The goal of this evaluate short, medium and long term outcome of the different embolization techniques in patients with primary and secondary hepatic tumors.
- Conditions
- Hepatocellular Carcinoma, Cholangiocarcinoma, Metastatic Colon Cancer, Metastatic Cancer
- Trial name
- LEATUM (NCT05714124)
- Testing
- Embolization
- Where
- Italy
- Volunteers
- 580 people
- Sponsor
- IRCCS San Raffaele
Metastatic Colon Cancer
Detection of Brain Metastasis by MRI in Metastatic Colorectal Cancer Patients
The aim of this study is to prospectively determine the incidence of brain metastases in metastatic colorectal cancer patients using systematic annual screening by MRI.
- Trial name
- NCT03694938
- Testing
- Magnetic resonance imaging
- Where
- 4 sites in France
- Volunteers
- 143 people
- Sponsor
- Poitiers University Hospital
MSI-H Colorectal Cancer, Melanoma
Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors
This is an open-label, parallel group, non-randomized, multicenter phase II study to evaluate the efficacy of spartalizumab (cohorts 1 and 2) and tislelizumab (cohort 3) in monotherapy in patients with PD1-high-expressing tumors.
- Conditions
- MSI-H Colorectal Cancer, Melanoma, Anal Carcinoma, Mesothelioma
- Trial name
- ACROPOLI (NCT04802876)
- Testing
- Spartalizumab, Tislelizumab
- Where
- Spain
- Volunteers
- 184 people
- Sponsor
- SOLTI Breast Cancer Research Group
Metastatic Colorectal Cancer
Efficacy And Safety Of Xeliri + Avastin Followed By Xelox + Avastin Or Reverse Sequence In Metastatic Colorectal Cancer
Since its introduction, 5-fluorouracil (5-FU) has been the cornerstone of treatment for metastatic colorectal cancer (mCRC). Meanwhile the oral 5FU pro-drug Capecitabine (Xeloda®) proved equivalence to 5-FU and is a well…
- Trial name
- PASSION (NCT02119026)
- Testing
- Capecitabine, Bevacizumab, Oxaliplatin
- Where
- Austria
- Volunteers
- 120 people
- Sponsor
- Prof. Dr. Werner Scheithauer
Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma
A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma
The primary purpose of this study is to evaluate the safety of GDC-7035 as a single agent and in combination with other anti-cancer therapies in participants with KRAS G12D-mutated metastatic colorectal cancer (CRC) or pancreatic…
- Trial name
- NCT07859085
- Testing
- GDC-7035, Panitumumab, mFOLFOX6
- Volunteers
- 388 people
- Sponsor
- Genentech, Inc.
Liver Metastasis Colon Cancer
TACE Associated to Systemic Bevacizumab for the Treatment of Refractory Liver Metastases From Colorectal Cancer
Transarterial chemoembolization (TACE) is an effective, minimally invasive therapy that is widely used for unresectable colorectal cancer liver metastases (CRC-LM) treatment.
- Trial name
- EMBOBEVA (NCT03732235)
- Testing
- TACE+ systemic Bevacizumab, FOLFIRI+Bevacizumab, TACE
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Giammaria Fiorentini
CRC (Colorectal Cancer)
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
The purpose of this study is to evaluate the efficacy and safety of standard-of-care chemotherapy and bevacizumab with or without INCA33890 in the first-line treatment of metastatic microsatellite stable colorectal cancer.
- Trial name
- NCT07284849
- Testing
- INCA33890, Bevacizumab, FOLFOX
- Where
- 297 sites in United States, Argentina and 20 more
- Volunteers
- 700 people
- Sponsor
- Incyte Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.